Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : DATE OF BOARD MEETING(H SHARES)

share with twitter share with LinkedIn share with facebook
03/18/2020 | 04:25am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

DATE OF BOARD MEETING

The board of directors (the ''Board'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') hereby announces that a meeting of the Board will be held on Monday, 30 March 2020, for the purposes of considering and approving the final results of the Company and its subsidiaries for the year ended 31 December 2019, recommendation of a final dividend, if any, and transacting any other business.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, People's Republic of China

18 March 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang and Ms. Mu Haining; and the independent non- executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

  • for identification purposes only

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 18 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 March 2020 09:21:06 UTC

share with twitter share with LinkedIn share with facebook
Latest news on SHANGHAI FOSUN PHARMACEUTI
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
08/06AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
08/06AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
08/05BIONTECH : Shanghai Fosun Pharma Dose Participants in China Covid-19 Vaccine Tri..
DJ
08/05SHANGHAI FOSUN PHARMACEUTICAL : BioNTech, Fosun launch another COVID-19 vaccine ..
RE
07/30SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
07/27SHANGHAI FOSUN PHARMACEUTICAL : Says Covid-19 Vaccine in Phase 1 Clinical Trial
DJ
07/15SHANGHAI FOSUN PHARMACEUTICAL : China gives the go-ahead for human trials of Bio..
RE
07/15China gives the go-ahead for human trials of BioNTech's COVID vaccine candida..
RE
07/14SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces its Licensed COVID-19 Vac..
PU
More news
Financials
Sales 2020 32 396 M 4 656 M 4 656 M
Net income 2020 3 545 M 510 M 510 M
Net Debt 2020 13 549 M 1 948 M 1 948 M
P/E ratio 2020 50,0x
Yield 2020 0,59%
Capitalization 159 B 22 847 M 22 833 M
EV / Sales 2020 5,32x
EV / Sales 2021 4,53x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 32,91 CNY
Last Close Price 69,70 CNY
Spread / Highest target -39,7%
Spread / Average Target -52,8%
Spread / Lowest Target -69,2%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP